Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Virus-Cell Interactions

The Pseudorabies Virus VP1/2 Tegument Protein Is Required for Intracellular Capsid Transport

G. W. Gant Luxton, Joy I-Hsuan Lee, Sarah Haverlock-Moyns, Joseph Martin Schober, Gregory Allan Smith
G. W. Gant Luxton
1Department of Microbiology-Immunology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joy I-Hsuan Lee
1Department of Microbiology-Immunology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Haverlock-Moyns
1Department of Microbiology-Immunology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Martin Schober
2Department of Cell and Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory Allan Smith
1Department of Microbiology-Immunology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: g-smith3@northwestern.edu
DOI: 10.1128/JVI.80.1.201-209.2006
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Description of VP1/2-null virus and VP1/2-complementing cell line. (A) Illustration of the PRV genome with characteristic internal and terminal repeats (IR and TR, respectively) shown as white rectangles. BamHI sites are indicated by vertical lollipops. The region of the genome relevant to this report is expanded to show the UL36 and UL37 ORFs, as well as the neighboring UL35 and UL38 ORFs (arrowheads indicate gene orientation). Below, dotted lines indicate regions deleted in the ΔUL36 (PRV-GS678) and ΔUL37 (PRV-GS993) viruses. (B) Ethidium bromide-stained agarose gel of BamHI-digested infectious clone DNAs isolated from E. coli and corresponding viral DNA isolated from nucleocapsids. The UL36 gene overlaps the two largest BamHI fragments of the viral genome, whereas the UL37 gene is exclusively on the second largest fragment. The FRT:kan:FRT insertion is ∼1.5 kbp and encodes two BamHI sites within the kanamycin resistance cassette, resulting in the truncation of the two large fragments during the ΔUL36 construction, and split of the second largest fragment into two smaller fragments during the ΔUL37 construction. Removal of the kanamycin resistance cassette and one FRT equivalent results in fusion of the remainders of the two largest fragments to produce the final ΔUL36 allele, and the reunion of the remainders of the second largest fragment to produce the final ΔUL37 allele. Additional fragment variations seen between the infectious clone plasmids and viral DNA result from loss of the E. coli vector backbone (as described in reference 36).

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Initial characterization of VP1/2- and UL37-null viruses and complementing cell lines. (A) Images of living PK15 cells 2 days posttransfection with infectious clones encoding fluorescent capsids (pGS575; “parent”) and clones carrying additional ΔUL36 (pGS678) or ΔUL37 (pGS993) mutations. (B) Images of living PK15 or complementing cells (as indicated) 2 days postinfection with viruses derived from the above three infectious clones (PRV-GS575, PRV-GS678, and PRV-GS993).

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Single-step growth kinetics of fluorescent-capsid viruses. (A) Comparison of the growth of the parent virus (PRV-GS575; circles) with the UL36 revertant virus (PRV-GS678R; squares). The ΔUL36 virus was not viable and therefore could not be examined. (B) Comparison of the growth of the parent virus (PRV-GS958; circles) with the ΔUL37 virus (PRV-GS993; triangles) and the UL37 revertant virus (PRV-GS993R; squares). Virions were harvested from the media (dashed lines; open symbols) and cells (solid lines; filled symbols) at the indicated times.

  • FIG. 4.
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    Nuclear egress of capsids into the cytoplasm. The percentage of living cells displaying cytoplasmic capsids 11 to 15 h postinfection is shown. Vero cells were infected with PRV-GS575, having intact UL36 and UL37 genes (“WT”), PRV-GS678 (ΔUL36), PRV-GS993 (ΔUL37), the PRV-GS678R revertant virus (UL36R), or the PRV-GS993R revertant virus (UL37R) at an MOI of ≤0.1. Because capsids near the nuclear rim could not be scored easily in this assay, cells were only counted as positive if at least 10 fluorescent-capsid punctae were observed in the cytoplasm. Error bars are standard error of the proportions (SEp). PRV-GS678 and PRV-GS993 were significantly different from each other and from each revertant virus (z < 0.01).

  • FIG. 5.
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    Transport of capsids in the cytoplasm. Individual moving fluorescent capsids were tracked in the cytoplasm of Vero cells at 18 hpi. Tracking was performed on time-lapse fluorescence recordings collected from a single focal plane at five frames/s. A profile of transport for each infection is shown by plots of the individual capsids tracked as distance from starting position in the first frame (y axis) versus time (x axis). Vero cells were infected with the following viruses: PRV-GS575 (A), PRV-GS678 (B), PRV-GS678R (C), PRV-GS993 (D), and PRV-GS993R (E). (F) Summary of data shown as percentage of tracked capsids that moved greater than 3, 4, 5, 6, 7, 8, and 9 μm from the origins for each infection (shown from left to right, respectively).

  • FIG. 6.
    • Open in new tab
    • Download powerpoint
    FIG. 6.

    Vero cell cytoskeleton susceptibility to cytochalasin D and nocodazole. Uninfected Vero cells were treated for 1 h with cytochalasin D, nocodazole, or both drugs together (or DMSO alone as control). Cells were fixed and processed for immunofluorescence imaging of filamentous actin and microtubules (image pairs).

  • FIG. 7.
    • Open in new tab
    • Download powerpoint
    FIG. 7.

    Dependence of cytoplasmic capsid transport on cytoskeleton integrity. Infected Vero cells were treated with cytochalasin D and nocodazole (or DMSO alone as control) at 17 hpi as indicated. (A to D) Individual moving cytoplasmic fluorescent capsids were tracked at 18 hpi and analyzed as described in the legend of Fig. 5. (E) Summary of data shown as a percentage of tracked capsids that moved greater than 3, 4, 5, 6, 7, 8, and 9 μm from the origins for each infection (shown from left to right). (F) Diffusion profiles of moving cytoplasmic capsids. The mean squared displacement of the capsids from origin is shown over the first 1.6 s of the recordings. Symbols are as follows: ▪, PRV-GS575 (“wild-type”); •, PRV-GS678: ΔUL36; □, PRV-GS575 + DMSO; ▿, PRV-GS575 + cytochalasin D; ▵, PRV-GS575 + nocodazole; ○, PRV-GS575 + cytochalasin D + nocodazole; ⋄, PRV-GS678 + cytochalasin D + nocodazole; ×, PRV-GS575 + cytochalasin D + nocodazole + azide. The error shown is 95% confidence.

Additional Files

  • Figures
  • HTML Page - index.htslp

    Files in this Data Supplement:

    • Supplemental file 1 - Movie S1. Live cell imaging of Vero cells infected with GFP-capsid virus encoding wild-type VP1/2. Although some cytoplasmic capsids display random motion, many transport directionally along curvilinear trajectories. The large fluorescent structures demarcate the nucleus, where capsids are assembled.
      QuickTime video, 2.6MB.
    • Supplemental file 2 - Movie S2. Live cell imaging of a Vero cell infected with VP1/2-null, GFP-capsid virus. Although all capsids move, the processive motion frequently observed with wild-type VP1/2 virus is absent here. Instead, capsids are limited to random motion.
      QuickTime video, 2.6MB.
PreviousNext
Back to top
Download PDF
Citation Tools
The Pseudorabies Virus VP1/2 Tegument Protein Is Required for Intracellular Capsid Transport
G. W. Gant Luxton, Joy I-Hsuan Lee, Sarah Haverlock-Moyns, Joseph Martin Schober, Gregory Allan Smith
Journal of Virology Dec 2005, 80 (1) 201-209; DOI: 10.1128/JVI.80.1.201-209.2006

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Pseudorabies Virus VP1/2 Tegument Protein Is Required for Intracellular Capsid Transport
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The Pseudorabies Virus VP1/2 Tegument Protein Is Required for Intracellular Capsid Transport
G. W. Gant Luxton, Joy I-Hsuan Lee, Sarah Haverlock-Moyns, Joseph Martin Schober, Gregory Allan Smith
Journal of Virology Dec 2005, 80 (1) 201-209; DOI: 10.1128/JVI.80.1.201-209.2006
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Capsid Proteins
Herpesvirus 1, Suid
Viral Fusion Proteins
viral structural proteins
virus assembly

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514